問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare (在職)

Division of Neurology

Division of Psychiatry

更新時間：2023-09-19

胡朝榮Hu, Chaur-Jong
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

Recruiting Trial

9Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

胡朝榮

List

17Cases

2017-12-15 - 2020-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2021-06-01 - 2028-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2023-12-21 - 2028-01-21

Phase II/III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2024-01-25 - 2029-01-31

Phase III

Active
A 52-Week, Open-Label Extension Study of ACP-204 in Adults with Alzheimer’s Disease Psychosis

  • Condition/Disease

    Alzheimer’s Disease Psychosis

  • Test Drug

    tablets

Participate Sites
7Sites

Recruiting7Sites

2022-12-01 - 2024-07-08

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2024-04-01 - 2028-12-31

Phase III

Active
Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease

  • Condition/Disease

    Alzheimer’s Disease

  • Test Drug

    injection

Participate Sites
11Sites

Recruiting11Sites

2024-02-01 - 2029-12-31

Phase III

Completed
Assessment of safety and efficacy of subcutaneous remternetug in early symptomatic Alzheimer’s disease

  • Condition/Disease

    Alzheimer’s disease

  • Test Drug

    injection

Participate Sites
7Sites

Recruiting7Sites

2025-01-01 - 2031-12-31

Phase III

Active
A Study of Remternetug Versus Placebo in Early Alzheimer’s Disease Participants at Risk for Cognitive and Functional Decline

  • Condition/Disease

    Early Alzheimer’s Disease

  • Test Drug

    injection

Participate Sites
12Sites

Recruiting12Sites

2012-05-01 - 2018-12-03

IIT

Phase III

Completed
Extending the time for Thrombolysis in Emergency Neurological Deficits

  • Condition/Disease

    Acute Ischaemic Stroke

  • Test Drug

    Tissue Plasminogen Activator (tPA)

Participate Sites
9Sites

Suspended8Sites

Study ended1Sites

蔡崇豪
China Medical University Hospital

Division of Neurology

2017-07-01 - 2022-07-30

Phase III

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease

  • Condition/Disease

    Mild Alzheimer's Disease

  • Test Drug

    Crenezumab

Participate Sites
7Sites

Terminated6Sites

黃錦章
Linkou Chang Gung Medical Foundation

Division of Neurology

胡朝榮
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Neurology

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB